OCTRI-supported researchers identify promising next-generation cancer treatment

Michael Cohen, PhD, in his lab with Moriah Arnold, an MD/PhD student. Both are at a basic science lab bench looking at a flask full of fluid.
Michael Cohen, Ph.D., in his lab with Moriah Arnold, an M.D./Ph.D. student and co-author of the study unveiling a new class of PARP-1 inhibitors.
Image Credit
OHSU/Christine Torres Hicks

Drugs known as PARP-1 inhibitors have emerged as an important but limited treatment option for certain cancers. Now, scientists at Oregon Health & Science University (OHSU) have uncovered a new class of PARP-1 inhibitors with unique and powerful anticancer properties that could make them more widely effective. Dr. Michael Cohen’s lab has discovered an exciting candidate for an anti-cancer drug — a molecule whose sticky properties make it toxic to cancer cells at very low doses. The discovery could improve both treatment for a variety of cancers and quality of life for patients.

The Oregon Clinical and Translational Research Institute (OCTRI), the CTSA hub at OHSU, supported the early stages of this work through the OCTRI Biomedical Innovation Program, which provides pilot funding, entrepreneur education, and project management support.